For consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Information about side effects is gathered in two stages:
When a new medicine is being developed, a series of clinical trials are run to see how effective the medicine is and also to identify side effects. These trials often involve comparing the medicine with a placebo.
As part of these trials, all participants are asked about how they feel. The questions aren’t simply related to the obvious and sought-after effects, but to all aspects of the participant’s health.
For example, a person in a trial for a new medicine for arthritis will be asked not only about pain and stiffness, but also about possible headache, nausea, itchy eyes, diarrhoea and many other facets of their health.
The researchers then record what proportion of participants mention any particular symptom. If the symptom occurs more often in those who took the medicine being tested than in those who took the placebo, then it is listed as a potential side effect of the medicine. The process is rigorous and systematic, and provides a lot of information about the side effects occurring in the types of people in the clinical trials.
When a medicine is going through the new drug approval process before it can be sold, all the information on its potential side effects must be sent to the regulatory authority responsible for approving the medicine. In Australia, this authority is the Therapeutic Goods Administration (TGA).
All the known side effects for a medicine have to be listed in its product information (PI) leaflet for health professionals, and its most significant side effects need to be included in the medicine’s consumer medicine information (CMI) leaflet.
You can search for and download the CMI leaflet, or you can ask your pharmacist. You can also search for the CMI or PI leaflets for your medicine on the TGA website.
Once the medicine is approved for use, it will be taken by a broader group of people in a wider range of circumstances than were involved in the initial clinical trials. Collecting information about side effects after a medicine has been approved for sale is called post-marketing surveillance.
This information is collected by the Therapeutic Goods Administration (TGA) from three sources:
All of this information helps to provide a clearer picture about the severity and frequency of the medicine’s side effects. However, because the information is collected from the general population, without any comparison group, it is harder to be sure whether new side effects are really caused by the medicine, or by something else.
There are a number of ways you can report side effects to the Therapeutic Goods Administration. These include:
Each report that the TGA receives is collected in a national database of adverse events. ‘Adverse events’ includes both side effects and other problems that may occur while using a medicine which turn out not to be a medicine-related side effect.
The information is regularly analysed so that any potential safety concerns can be investigated in detail. If the TGA identifies a new safety concern such as a new side effect, it can take action to address it and make sure that health professionals and the public are aware of it.
Always tell your health professional if you think you are having a side effect from your medicine. They may report new or unusual medicine-related side effects they observe or that are reported to them by their patients to the Therapeutic Goods Administration (TGA). Your personal information will remain confidential and your privacy maintained.
The AME Line is phone-in service that encourages members of the public to report and discuss side effects that might be related to their medicine. Medicine-related side effects are then reported to the Therapeutic Goods Administration (TGA) for assessment and contribute to national medicine safety efforts. Your personal information will remain confidential and your privacy maintained. Read more about the AME Line.
Date published: 2011-01-24 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.